TBPH Theravance Biopharma Inc

0.26 (2.85%)
Sep 25 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 592,854
Bid Price 9.03
Ask Price 9.40
News -
Day High 9.40


52 Week Range


Day Low 9.01
Company Name Stock Ticker Symbol Market Type
Theravance Biopharma Inc TBPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.26 2.85% 9.37 17:19:38
Open Price Low Price High Price Close Price Prev Close
9.10 9.01 9.40 9.37 9.11
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,158 592,854 $ 9.26 $ 5,487,627 - 8.755 - 12.03
Last Trade Time Type Quantity Stock Price Currency
16:07:44 1 $ 9.08 USD

Theravance Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
494.86M 52.81M - 51.35M 872.13M 16.51 0.57
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Theravance Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No TBPH Message Board. Create One! See More Posts on TBPH Message Board See More Message Board Posts

Historical TBPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.019.408.7558.99435,3350.364.0%
1 Month9.4510.188.7559.41530,412-0.08-0.85%
3 Months10.3010.598.7559.66430,752-0.93-9.03%
6 Months10.5612.038.75510.48513,834-1.19-11.27%
1 Year9.9312.038.75510.50571,154-0.56-5.64%
3 Years15.4722.746.1010.84681,377-6.10-39.43%
5 Years29.1635.486.1013.55528,176-19.79-67.87%

Theravance Biopharma Description

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).